Let's see how things are shaping up for this announcement. Mylan's stock has lost 3.3% in the last six months compared with the industry's decline of 6.3%. Factors to Consider This Quarter Mylan expects revenues of $11.75-$13.25 billion in …
He said the impact would have been more severe a year or two ago when Mylan was charging more for the devices. Shares of Mylan rose $1.46 to $36.83 in early afternoon trading on the New York Stock Exchange.
Glatopa, a generic version of Copaxone 20 mg, is being marketed by Momenta and Sandoz - Novartis’ (NVS - Free Report) generic arm - since 2015 while Mylan (MYL - Free Report) launched its version of the 20 mg formulation in October …
Mylan NV (NASDAQ:MYL) shares should be rising. Morgan Stanley upgraded Mylan stock just a few days ago, calling it the best pick among the domestic generic drugmakers. And, just this week Mylan announced it had launched an …
Mylan CEO Heather Bresch Mylan (MYL) reported Q4 revenue of $3.2 billion and EPS of $1.43. The company missed on revenue by $60 million, but beat on earnings. The stock was flat after the earnings announcement. I had the following …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
On the the heels of Mylan NV's (MYL) investor day, Leerink Partners LLC analyst Ami Fadia on Thursday, April 12, raised her rating on the drugmaker's stock to …
Shares of Mylan N.V. (NASDAQ: MYL) jumped on Tuesday after a key analyst came forward in favor of this pharmaceutical giant. This stock has been through the ringer over the past couple of years, but by the looks of it, Mylan could be …